Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Two policemen injured at religious youth protest in Jerusalem marking Ahuvia Sandak's death - 2New findings suggest atmosphere could exist on exoplanet TOI-561b
- 3Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- 4South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- 55 things for parents to know about changes to kids vaccine schedule
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Vote in favor of your #1 Sort of Convenience for a Family
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- Artemis II crew cleared to depart Earth orbit, head for moon
- The Solution to Ecological Protection: Saving Nature for People in the future
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
